Who
Robert Charles Breedlove
Principal Accounting Officer
Company insider
Files Form 4 as: Principal Accounting Officer, Phathom Pharmaceuticals.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $27K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 19 May 2025
- Last trade
- 3 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Jul 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 8 Sep 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $4,163460 at $9.05 | filing |
| 3 Sep 2026filed 8 Sep 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $4,163460 at $9.05 | filing |
| 14 Jul 2026filed 16 Jul 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $17K1,555 at $11.04 | filing |
| 14 Jul 2026filed 16 Jul 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $17K1,555 at $11.04 | filing |
| 27 Feb 2026filed 3 Mar 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —2,790 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $12K964 at $12.56 | filing |
| 27 Feb 2026filed 3 Mar 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $5,200414 at $12.56 | filing |
| 27 Feb 2026filed 3 Mar 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —2,790 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $12K964 at $12.56 | filing |
| 27 Feb 2026filed 3 Mar 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $5,200414 at $12.56 | filing |
| 21 Jan 2026filed 23 Jan 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $11K776 at $13.61 | filing |
| 21 Jan 2026filed 23 Jan 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $11K776 at $13.61 | filing |
| 18 Dec 2025filed 19 Dec 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $3,744230 at $16.28 | filing |
| 3 Nov 2025filed 5 Nov 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,079524 at $13.51 | filing |
| 5 Sep 2025filed 9 Sep 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5,573461 at $12.09 | filing |
| 16 Jul 2025filed 18 Jul 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $14K1,692 at $8.36 | filing |
| 19 May 2025filed 21 May 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
News
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026PHAT · manilatimes.net · 19 Oct 2026Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsPHAT · dailypolitical.com · 11 Oct 2026Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific MeetingPHAT · manilatimes.net · 8 Oct 2026
0 headlines in the last 90 days name Robert Charles Breedlove; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.